published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsChandan, 2020 0.85 [0.61; 1.19] 0.85[0.61; 1.19]Chandan, 202010%17,190NAnot evaluable confirmed COVID (any severity)detailed resultsGendelman, 2020 1.10 [0.50; 2.40] 1.10[0.50; 2.40]Gendelman, 202010%14,520NAnot evaluable new illness compatible with Covid-19 detailed resultsChandan, 2020 0.79 [0.57; 1.10] 0.79[0.57; 1.10]Chandan, 202010%17,190NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-14 20:15 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290